PSA-based early detection of prostate cancer

被引:11
|
作者
Luboldt, HJ [1 ]
Rübben, H [1 ]
机构
[1] Univ Essen Gesamthsch, Urol Klin & Poliklin, D-45122 Essen, Germany
来源
UROLOGE A | 2000年 / 39卷 / 01期
关键词
prostate-specific antigen; early detection; prostate cancer;
D O I
10.1007/s001200050005
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Prevention of prostate cancer up to now is not possible, advanced stages of prostate cancer are not curable. About 13 000 men a year die of prostate cancer in Germany. PSA-based screening has been shown to be effective in detecting prostate cancer at an early, potentially curable stage; however, this tumor marker is limited by appreciable false-positive and false-negative results. Several PSA-related indexes may improve the power of PSA in early detection: As PSA density, age-adjusted PSA, and percent free PSA. These indexes can improve positive predictive value of PSA-testing, but are not able to differentiate carcinoma from benign hyperplasia on an individual basis. Men presenting for early detection have to be informed about possible overtreatment before undergoing biopsy to further investigate increased PSA above 4.0 ng/ml or suspect findings in digital rectal examination.
引用
收藏
页码:22 / 26
页数:9
相关论文
共 50 条
  • [1] PSA-based early detection of prostate cancer
    Albers, Peter
    Arsov, Christian
    Hiester, Andreas
    Quentin, Michael
    Schimoeller, Lars
    Antoch, Gerald
    Rabenalt, Robert
    [J]. ONKOLOGE, 2016, 22 (08): : 558 - 561
  • [2] Current results on PSA-based prostate cancer detection
    Graefen, M.
    Schlomm, T.
    Steuber, T.
    Sauter, G.
    [J]. BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2014, 57 (03) : 312 - 317
  • [3] PSA-based screening for prostate cancer
    Byrne, Derek
    [J]. TRENDS IN UROLOGY & MENS HEALTH, 2013, 4 (01) : 12 - 12
  • [4] IMPROVING PSA-BASED PROSTATE CANCER DETECTION WITH THE PROSTATE HEALTH INDEX (PHI)
    Stephan, Carsten
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S156 - S156
  • [5] Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future
    Hendrik Van Poppel
    Tit Albreht
    Partha Basu
    Renée Hogenhout
    Sarah Collen
    Monique Roobol
    [J]. Nature Reviews Urology, 2022, 19 : 562 - 572
  • [6] Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future
    Van Poppel, Hendrik
    Albreht, Tit
    Basu, Partha
    Hogenhout, Renee
    Collen, Sarah
    Roobol, Monique
    [J]. NATURE REVIEWS UROLOGY, 2022, 19 (09) : 562 - 572
  • [7] PSA-based vaccines for the treatment of prostate cancer
    Madan, Ravi A.
    Gulley, James L.
    Arlen, Philip M.
    [J]. EXPERT REVIEW OF VACCINES, 2006, 5 (02) : 199 - 209
  • [8] Diagnostic value of biparametric MRI as an adjunct to PSA-based detection of prostate cancer
    Rais-Bahrami, Soroush
    Siddiqui, Minhaj
    Vourganti, Srinivas
    Turkbey, Baris
    Rastinehad, Ardeshir
    Stamatakis, Lambros
    Truong, Hong
    Walton-Diaz, Annerleim
    Hoang, Anthony N.
    Nix, Jeffrey
    Merino, Maria
    Wood, Bradford J.
    Simon, Richard
    Choyke, Peter L.
    Pinto, Peter A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [9] Implementation of PSA-based active surveillance in prostate cancer
    Jalloh, Mohamed
    Cooperberg, Matthew R.
    [J]. BIOMARKERS IN MEDICINE, 2014, 8 (05) : 747 - 753
  • [10] Unintended consequences of decreased PSA-based prostate cancer screening
    Ahlering, Thomas
    Huynh, Linda My
    Kaler, Kamaljot S.
    Williams, Stephen
    Osann, Kathryn
    Joseph, Jean
    Lee, David
    Davis, John W.
    Abaza, Ronney
    Kaouk, Jihad
    Patel, Vipul
    Kim, Isaac Yi
    Porter, James
    Hu, Jim C.
    [J]. WORLD JOURNAL OF UROLOGY, 2019, 37 (03) : 489 - 496